Papaverine bufus solution for injection Renewal 20mg/ml 2ml ampoules, 10pcs

Composition

Active ingredient: Papaverine Hydrochloride-20,00 mgsupport substances: disodium edetate (trilon B) – 0.05 mg methionine-0.10 mg water for injection-up to 1 ml

Pharmacological action

Pharmacotherapy group: antispasmodic agent. ATX code: A 0 ZD01 Pharmacological propertiespharmacodynamicapaverine reduces smooth muscle tone and has a vasodilating and antispasmodic effect in this regard. It is an inhibitor of the enzyme phosphodiesterase and causes intracellular accumulation of cyclic 3,5-adenosine monophosphate, which leads to impaired contractility of smooth muscles and their relaxation in spastic conditions. The effect of papaverine on the central nervous system is weak, only in large doses it has some sedative effect. In large doses, it reduces the excitability of the heart muscle and slows down intracardiac conduction. Pharmacokineticadsorption depends on the dosage form. The average bioavailability is 54%. Plasma protein binding is 90%. It is well distributed and penetrates through histohematic barriers. It is metabolized in the liver. T 1/2 – 0,5-2 hours (can be extended up to 24 hours). It is excreted by the kidneys in the form of metabolites. Completely removed from the blood during hemodialysis.

Indications

Spasms of smooth muscles of the abdominal cavity, peripheral vessels and brain vessels, urinary tract, renal colic. It is used as an auxiliary agent for premedication.

Contraindications

Comatose state, respiratory depression, violation of atrioventricular conduction; age up to 1 year; hypersensitivity to the drug. Glaucoma, severe liver failure, advanced age (risk of hyperthermia). With caution Conditions after traumatic brain injury, chronic renal failure, adrenal insufficiency, hypothyroidism, prostatic hyperplasia, supraventricular tachycardia, shock conditions.

Side effects

Possible: allergic reactions, decreased blood pressure, increased activity of “hepatic” transaminases, eosinophilia, drowsiness, headache, nausea, constipation, increased sweating. With rapid intravenous use, as well as with the use of high doses, atrioventricular block and cardiac arrhythmia may develop.

Interaction

Papaverine reduces the antiparkinsonian effect of levodopa, reduces the hypotensive effect of methyldopa. In combination with barbiturates, the antispasmodic effect of papaverine hydrochloride is enhanced. When combined with tricyclic antidepressants, novocainamide, reserpine, quinidine sulfate, it is possible to increase the hypotensive effect.

How to take, course of use and dosage

The drug is administered intramuscularly or intravenously. A single dose for adults is 0.02-0.04 g (1-2 ml of 2% solution); the interval between injections is at least 4 hours. Intravenous use is performed by pre-diluting a 2% solution of the drug with 10-20 ml of isotonic sodium chloride solution. For children aged 1 to 12 years, the maximum single dose is 0.3 mg / kg of body weight.

Overdose

Symptoms: diplopia, weakness, low blood pressure, drowsiness. Treatment: symptomatic (maintenance of blood pressure).

Special instructions

Intravenously, the drug should be administered slowly and under the supervision of a doctor.

During the treatment period, alcohol intake should be excluded. During pregnancy and lactation, the safety of the drug has not been established.

Form of production

Solution for injection

Storage conditions

Store in a dark place.

Shelf

life is 3 years.

Active ingredient

Papaverine

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection

Description

For children as prescribed by a doctor, For adults

Indications

Hypertension, Gastrointestinal Spasm, Biliary Dyskinesia, Bronchospasm, Cholecystitis, Cholelithiasis, Colitis, Urolithiasis